Psychosocial Functioning in Patients with Schizophrenia Treated with Aripiprazole – an Office-based Real-world Setting. Results from the German Post-marketing Surveillance Study

Abstract

Aim: Aripiprazole (ABILIFY^®) is an effective antipsychotic used in a dose range from 10 to 30 mg, administered once daily. Soon after its approval in Germany for treatment of schizophrenia, a 12-month post-marketing surveillance study was initiated that included 1 096 patients cared for by 408 office-based psychiatrists and/or neurologists in private practice. The aim was to gain further insights into safety and efficacy of aripiprazole in an outpatient real-life setting focusing on general health, well-being and psychosocial functioning.

Patients and Methods: Efficacy was rated by using standard CGI, SF-12^® and SIWM-PsySo^® instruments for severity of disease, physical and mental health outcomes and psychosocial state, respectively. Safety was evaluated according to the reports of adverse events. Mean total daily dose of aripiprazole increased from 15.4 mg at the visit after 1 month to 17.6 mg at the visits after 6 to 12 months, the most frequently administered maintenance dose being 15 mg.

Results and Discussion: Within the observation period significant improvements of CGI, SF-12^® and SIWM-PsySo^® scores over time versus baseline values were observed (p<0.001) when starting with or switching to aripiprazole. Physicians observed improvements in 80.7% of the patients at endpoint; in 62% of the patients the disease state was considered “much” or “very much” improved. Aripiprazole was overall well tolerated; 19.9% of patients discontinued treatment after 12 months. Adverse effects in general were moderate to mild and corresponded to the known tolerability profile of aripiprazole. Psychotic side effects reported were probably due to a recurrence of the underlying schizophrenic disorder.

Conclusion: The results indicate that aripiprazole may be an efficacious and safe treatment option for pre-treated patients with schizophrenia also in a naturalistic psychiatrist/neurologist practice setting with effects on health and psychosocial functioning and a comparably low dropout rate.

References

• 1 Andreasen NC, Carpenter  Jr  WT, Kane JM. et al . Remission in schizophrenia: proposed criteria and rationale for consensus.  Am J Psychiatry. 2005;  162 441-449
• 2 Beuzen J-N, Schirr K, Pans M. et al .Effectiveness of aripiprazole in a naturalistic setting: a european multicenter study. 13th Biennial Winter Workshop on Schizophrenia Research. Davos, Switzerland 2006
• 3 Bullinger M, Kirchberger I. Der SF-36 Fragebogen zum Gesundheitszustand. Handbuch für die deutschsprachige Fragebogenversion. Göttingen: Hogrefe Verlag für Psychologie 1998
• 4 Burris KD, Molski TF, Xu C. et al . Aripiprazole, a novel antipsychotic drug, is a high affinity partial agonist at human dopamine D2 receptors.  J Pharmacol Exp Ther. 2002;  302 381-389
• 5 Dickinson D, Bellack AS, Gold JM. Social/communication skills, cognition, and vocational functioning in schizophrenia.  Schizophr Bull. 2007;  33 1213-1220
• 6 Eack SM, Newhill CE. Psychiatric Symptoms and quality of life in schizophrenia: a meta-analysis.  Schizophr Bull. 2007;  33 1225-1237
• 7 Fan X, Henderson DC, Chiang E. et al . Sexual functioning, psychopathology and quality of life in patients with schizophrenia.  Schizophr Res. 2007;  94 119-127
• 8 Fleischhacker WW. Aripiprazole.  Expert Opin Pharmacother. 2005;  6 2091-2101
• 9 Fuchs J, Steinert T. Patients with a first episode of schizophrenia spectrum psychosis and their pathways to psychiatric hospital care in South Germany.  Soc Psychiatry Psychiatr Epidemiol. 2004;  39 375-380
• 10 Gründer G, Kungel M, Ebrecht M. et al . Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.  Pharmacopsychiatry. 2006;  39 ((Suppl. 1)) S21-25
• 11 Guy W. Clinical Global Impressions scale. In: US Dept Health E, and Welfare publication (AMD) ed, ECDEU Assessment Manual for Psychopharmacology. Rockville: National Institute of Mental Health 1976: 221-227
• 12 Hanssen L, L’Italien G, MacQuade R. et al .Evaluation of quality of life in community-treated schizophrenic patients: a naturalistic open-label study comparing aripiprazole to standard-of-care. (Schizophrenia Trial of Aripiprazole: Star Study). 14th European Congress of Psychiatry. Nice, France 2006
• 13 Hirose T, Uwahodo Y, Yamada S. et al . Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile.  J Psychopharmacol. 2004;  18 375-383
• 14 Hofer A, Rettenbacher MA, Widschwendter CG. et al . Correlates of subjective and functional outcomes in outpatient clinic attendees with schizophrenia and schizoaffective disorder.  Eur Arch Psychiatry Clin Neurosci. 2006;  256 246-255
• 15 Jordan S, Koprivica V, Chen R. et al . The antipsychotic aripiprazole is a potent, partial antagonist at the human 5-HT1A receptor.  Eur J Pharmacol. 2002;  441 137-140
• 16 Kane JM, Meltzer HY, Carson WH. et al . Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.  J Clin Psychiatry. 2007;  68 213-223
• 17 Kerwin R, Millet B, Herman E. et al . A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients – Schizophrenia Trial of Aripiprazole: (STAR) study.  Eur Psychiatry. 2007;  22 433-443
• 18 Klein N, Wallner H, Kasper S. Aripiprazol – ein partieller Dopamin-Agonist als neues Antipsychotikum.  Psychopharmakotherapie. 2006;  13 49-54
• 19 Kompetenznetz Schizophrenie . Projektverbund II (PV II), Teilverbund 2: Optimierung der Langzeitbehandlung. http://www.kompetenznetzschizophrenie.de/rdkns/653_14.htm , Accessed 11.04.2008
• 20 Lambert M, Naber D. Current issues in schizophrenia: overview of patient acceptability, functioning capacity and quality of life.  CNS Drugs. 2004;  18 ((Suppl. 2)) 5-17 , discussion 41–43
• 21 Lambert M, Riedel M, Möller H-J. et al . Das Antipsychotikum Aripiprazol Wirksamkeit und Verträglichkeit.  Psychiatrie. 2004;  1 50-62
• 22 Lenroot R, Bustillo JR, Lauriello J. et al . Integrated treatment of schizophrenia.  Psychiatr Serv. 2003;  54 1499-1507
• 23 Leucht S, Lasser R. The concepts of remission and recovery in schizophrenia.  Pharmacopsychiatry. 2006;  39 161-170
• 24 Liberman RP. Coping with chronic mental disorders: a framework for hope. In: Liberman RP, ed. Psychiatric rehabilitation of chronic mental patients. Washington, DC: American Psychiatric Press 1988: 1-28
• 25 Liberman RP, Mueser KT, Wallace CJ. et al . Training skills in the psychiatrically disabled: learning coping and competence.  Schizophr Bull. 1986;  12 631-647
• 26 Lieberman JA, Stroup TS, MacEvoy JP. et al . Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.  N Engl J Med. 2005;  353 1209-1223
• 27 Marder SR, MacQuade RD, Stock E. et al . Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials.  Schizophr Res. 2003;  61 123-136
• 28 MacEvoy JP, Lieberman JA, Stroup TS. et al . Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment.  Am J Psychiatry. 2006;  163 600-610
• 29 Melle I, Friis S, Hauff E. et al . Social functioning of patients with schizophrenia in high-income welfare societies.  Psychiatr Serv. 2000;  51 223-228
• 30 Messer T, Schmauss M, Spevakne-Goeroecs T. et al . Clinical use of aripiprazole in patients with schizophrenia – a real-life setting. Results from the German Postmarketing Surveillance Study.  W J Biol Pschiatry. 2007;  1-8
• 31 Morrison RL, Bellack AS. Social functioning of schizophrenic patients: clinical and research issues.  Schizophr Bull. 1987;  13 715-725
• 32 Nuechterlein KH, Dawson ME. A heuristic vulnerability/stress model of schizophrenic episodes.  Schizophr Bull. 1984;  10 300-312
• 33 Sanderson K, Andrews G. Prevalence and severity of mental health-related disability and relationship to diagnosis.  Psychiatr Serv. 2002;  53 80-86
• 34 Stroup TS, Lieberman JA, MacEvoy JP. et al . Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic.  Am J Psychiatry. 2006;  163 611-622
• 35 Swartz MS, Perkins DO, Stroup TS. et al . Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study.  Am J Psychiatry. 2007;  164 428-436
• 36 Tandon R, Marcus RN, Stock EG. et al . A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).  Schizophr Res. 2006;  84 77-89
• 37 Tulloch AD, Fearon P, David AS. Social outcomes in schizophrenia: from description to action.  Curr Opin Psychiatry. 2006;  19 140-144
• 38 Os J van, Driessen G, Gunther N. et al . Neighbourhood variation in incidence of schizophrenia. Evidence for person-environment interaction.  Br J Psychiatry. 2000;  176 243-248
• 39 Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity.  Med Care. 1996;  34 220-233
• 40 Ware JE, Kosinski M, Keller SD. How to Score the SF-12 Physical and Mental Health Summary Scales. Boston: The Health Institute, New England Medical Center 1998
• 41 West JC, Wilk JE, Olfson M. et al . Patterns and quality of treatment for patients with schizophrenia in routine psychiatric practice.  Psychiatr Serv. 2005;  56 283-291
• 42 World Health Organisation .International statistical classification of diseases and related health problems, 10th revision. Geneva 2007
• 43 Yanos PT, Moos RH. Determinants of functioning and well-being among individuals with schizophrenia: an integrated model.  Clin Psychol Rev. 2007;  27 58-77
• 44 Zubin J, Spring B. Vulnerability – a new view of schizophrenia.  J Abnorm Psychol. 1977;  86 103-126

Correspondence